There’s a new birth control method, and this documentary asks men to take the title of the film seriously.

IFLScience met L. R. Fox of NEXT Life Sciences to learn about their latest promising clinical trial results for Plan A™ and PausePill™.

Violet Benson speaks with Founder and Chairman of NEXT Life Sciences, L.R. Fox, on the Daddy Issues Podcast to talk about Plan A™, PausePill™, and the future that couples could experience with male birth control.

Charlie Sabgir from the Young Men Research Project speaks with with Founder of Plan A™, L.R. Fox, about the past, present, and future of male birth control options.

Long limited to condoms and vasectomy, male contraception could soon have new options. Several methods are advancing in clinical trials, paving the way for more balanced sharing of responsibility between men and women.

Plan A™ by NEXT Life Sciences offers a reversible, non-hormonal male contraceptive using Vasalgel®. Men, couples, and physicians are embracing it as a solution to a long-unmet need.

Advancing Plan A™ alongside NLS-133, NEXT Life Sciences is responding directly to a long-unmet need, expanding contraceptive choice for men and couples worldwide.

Currently, the only widely used forms of contraception available to men are condoms and vasectomies. There’s a substantial potential market for other methods.

Newly issued patent covers a new medical device and method to deliver and remove hydrogel within the body, including Plan A™’s sperm occlusion system.

NEXT Life Sciences has been part of the StartUp Health community since 2022, advancing work that cuts across multiple Health Moonshots, from Men’s Health and Women’s Health to Access to Care. As Dr. Walley puts it, “The world is ready for a modern, non-hormonal, fully reversible male contraceptive.” The next chapters in this story may change reproductive health forever.

Investment in medical/health issues is a long-term proposition. We talk to those making a health treatment focused on male contraception.

Peter Barton Hutt, former Chief Counsel at the FDA and pioneer of medical device regulatory policy, joins as Plan A™ concludes successful clinical trials.

We spoke to Darlene Walley, CEO of Next Life Sciences, about Plan A, the need it is addressing, and why she expects men and women to see it as a welcome alternative to current choices.

“Finally, we’re close to men sharing more of this responsibility.” - Dr. Wendy Walsh

As a leader in this emerging field, I often get announcements of breakthrough technologies. A recent email grabbed my attention: “Male Contraceptive Plan A Completes First North American Clinical Trial with 100% Success.”

Physicians from Canada and Australia have tested the Plan A™ male birth control delivery system with 100% success in 50 men.

In this groundbreaking interview, Dr. Darlene Walley—biotech leader and CEO of NEXT Life Sciences—shares the bold vision behind Plan A™, the world’s first long-lasting, non-hormonal, and reversible male contraceptive in development.

Australian Clinical Results Demonstrate 100% Success Rate for New Delivery Method

NEXT Life Sciences is raising $20 million to develop male contraceptive product Plan A, CEO Darlene Walley tells Axios exclusively.